COPD - The disease and non-drug treatment

Hospital Pharmacist

Volumn 11, Issue 9, 2004, Pages 359-364

  Ohri, Chandra M ^a   Steiner, Michael C ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID;

AIRWAY OBSTRUCTION; ANXIETY; ASSISTED VENTILATION; CAUSE OF DEATH; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DEPRESSION; DISEASE EXACERBATION; EMPHYSEMA; FORCED EXPIRATORY VOLUME; HUMAN; LUNG RESECTION; LUNG TRANSPLANTATION; PATHOPHYSIOLOGY; PREVALENCE; RESPIRATORY FAILURE; REVIEW; SPIROMETRY; UNITED KINGDOM; WEIGHT REDUCTION;

EID: 6344264975     PISSN: 13527967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997;349:1498-504.
2. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease. American Journal of Respiratory and Critical Care Medicine 2001;163:1256-76.
3. National Institute for Clinical Excellence. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: The Institute; 2004.
4. Laennec RHT. A treatise on the diseases of the chest and medical auscultation. London: Longman; 1834.
5. Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes J, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000;55:789-94.
6. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000;117(Suppl 2):1S-4S.
7. Britton M. The burden of COPD in the UK: results from the confronting COPD survey. Respiratory Medicine 2003;97(Suppl C):S71-S79.
8. Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. European Respiratory Journal 1999;13:1109-14.
9. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480-5.
10. Fletcher CM, Elmes PC, Fairburn MB, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. BMJ 1959;(5147):257-66.
11. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chrome obstructive pulmonary disease. New England Journal of Medicine 2004;350:1005-12.
12. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977;(6077):1645-8.
13. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
14. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. American Review of Respiratory Disease 1993;147:1151-6.
15. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996;51:819-24.
16. American Thoracic Society. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. American Journal of Respiratory and Critical Care Medicine 1999;159(4 Pt 2):S1-40.
17. van Ede L, Yzermans CJ, Brouwer HJ. Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review. Thorax 1999;54:688-92.
18. Royal College of Physicians. Domiciliary oxygen therapy services. Clinical guidelines and advice for prescribers. London: Royal College of Physicians; 1999.
19. Eaton T, Garrett JE, Young P, Fergusson W, Kolbe J, Rudkin S, et al. Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study. European Respiratory Journal 2002;20:306-12.
20. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. New England Journal of Medicine 2003;348:2059-73.
21. Lacasse Y, Brosseau L, Milne S, Martin S, Wong E, Guyatt GH, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Library 2002; issue 3.
22. Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000;355:362-8.
23. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS. Nutritional support for individuals with COPD: a meta-analysis. Chest 2000;117:672-8.
24. Steiner MC, Barton RJL, Singh SJ, Morgan MD. The nutritional enhancement of exercise performance in chronic obstructive pulmonary disease. A randomised controlled trial. Thorax 2003;58:745-51.
25. Ram FS, Wedzicha JA, Wright J, Greenstone M. Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ 2004;329:315.
26. Ram F, Picot J, Lightowler J, Wedzicha J. Noninvasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Library 2004; issue 3.
27. Plant PK, Owen JL, Elliott MW. Early use of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000;355:1931-5.